Table 5. Data from 41.5 ± 14 months' follow-up.

Characteristic	Total (n = 100)	Unfractionated heparin (n = 50)	Bivalirudin (n = 50)
MACE, n (%)	22 (22)	11 (22)	11 (22)
Reinfarction, n (%)	16 (16)	7 (14)	9 (18)
Death from any reason, n (%)	7 (7)	5 (10)	2 (4)
Target vessel revascularization, n (%)	15 (15)	8 (16)	7 (14)
Cardiac rehospitalization, n (%)	52 (52)	25 (50)	27 (54)
Noncardiac rehospitalization, n (%)	54 (54)	22 (44)a	32 (64)*

Abbreviation: MACE, major adverse cardiac event.

^a p = 0.056.